Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67

Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results

November 9, 2016 4:01 PM EST

REDWOOD CITY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2016.

Corporate Highlights for the Third Quarter 2016 Include:Oncology therapeutic franchise:

CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) U.S. Food and Drug Administration filing of the CHS-1701 biologics license application (BLA).Positive topline results from follow-on pharmacokinetic and pharmacodynamic (PK/PD) clinical study CHS-1701-05.  All co-primary endpoints for PK, Cmax and Area Under the Curve (AUC), and PD, absolute... More